Characterization of risk of HIV and HIV outcomes in the Brazilian Sickle Cell Disease (SCD) population and comparison of SCD outcomes between HIV sero-positive and negative SCD patients

ICR 201509-0925-003

OMB: 0925-0736

Federal Form Document

ICR Details
0925-0736 201509-0925-003
Historical Active
HHS/NIH
Characterization of risk of HIV and HIV outcomes in the Brazilian Sickle Cell Disease (SCD) population and comparison of SCD outcomes between HIV sero-positive and negative SCD patients
New collection (Request for a new OMB Control Number)   No
Regular
Approved with change 03/11/2016
Retrieve Notice of Action (NOA) 09/30/2015
  Inventory as of this Action Requested Previously Approved
03/31/2019 36 Months From Approved
650 0 0
325 0 0
0 0 0

The limited studies focused on HIV in SCD have suggested a lower prevalence of HIV in SCD compared to a non-SCD population. While some investigators have suggested that perhaps SCD pathophysiology has a unique effect on HIV infection or replication, none of the studies adequately measured risk of HIV in SCD. Objective 1 of the proposed study is to compare HIV risk factors between 150 SCD cases randomly selected from the REDS-III Brazilian SCD Cohort and 150 controls from a demographically similar population. An assessment that has been well validated in previous REDS-II HIV studies has been modified for the SCD population and will be used to collect data regarding HIV risk behaviors. Objective 2 will seek to enroll approximately 25 SCD patients diagnosed with HIV infection as part of routine clinical care at REDS-III participating centers in the previous 10 years and abstract detailed information regarding the HIV infection and SCD from medical records. This will allow a detailed case series description of HIV outcomes in this population (Objective 2a). Finally, HIV negative controls matched on age, gender, SCD type and center to the identified HIV sero-positive SCD patients will be selected from the REDS-III SCD cohort to compare SCD outcomes between HIV positive and HIV negative subjects (Objective 2b). The HIV negative controls have already consented to participate in REDS-III research; therefore, their SCD outcomes will be extracted from the REDS-III SCD cohort dataset. No re-contact will be required, and no assessment will be administered to this group of HIV negative controls. This study will provide critical information to guide the management and future research for patients with HIV and SCD in Brazil, the United States and worldwide.

US Code: 42 USC Chapter 6A, sect. 285b-1 Name of Law: NHLBI Purpose
  
None

Not associated with rulemaking

  80 FR 32388 06/08/2015
80 FR 55141 09/14/2015
No

  Total Approved Previously Approved Change Due to New Statute Change Due to Agency Discretion Change Due to Adjustment in Estimate Change Due to Potential Violation of the PRA
Annual Number of Responses 650 0 0 650 0 0
Annual Time Burden (Hours) 325 0 0 325 0 0
Annual Cost Burden (Dollars) 0 0 0 0 0 0
Yes
Miscellaneous Actions
No
new submission

$38,114
Yes Part B of Supporting Statement
No
No
No
No
Uncollected
Mikia Currie 3014350941

  No

On behalf of this Federal agency, I certify that the collection of information encompassed by this request complies with 5 CFR 1320.9 and the related provisions of 5 CFR 1320.8(b)(3).
The following is a summary of the topics, regarding the proposed collection of information, that the certification covers:
 
 
 
 
 
 
 
    (i) Why the information is being collected;
    (ii) Use of information;
    (iii) Burden estimate;
    (iv) Nature of response (voluntary, required for a benefit, or mandatory);
    (v) Nature and extent of confidentiality; and
    (vi) Need to display currently valid OMB control number;
 
 
 
If you are unable to certify compliance with any of these provisions, identify the item by leaving the box unchecked and explain the reason in the Supporting Statement.
09/30/2015


© 2024 OMB.report | Privacy Policy